MetaCap

Cabaletta Bio Inc. Company Profile

NASDAQ: CABAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.9361-0.0739 (-7.32%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Cabaletta Bio at a glance

Cabaletta Bio Inc. (NASDAQ: CABA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Philadelphia, PA. Cabaletta Bio is led by Dr. Steven A. Nichtberger M.D. and employs about 154 people. The company's shares have traded publicly since 2019.

At a market capitalization of $201.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001759138, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Cabaletta Bio do?

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Business description based on the company's public filings.

Company information

Legal name
Cabaletta Bio Inc.
Ticker
NASDAQ: CABA
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Steven A. Nichtberger M.D.
Employees
154
Headquarters
2929 Arch Street, Philadelphia, PA, United States
Phone
267 759 3100
IPO year
2019
Market cap
$201.94M
SEC CIK
0001759138
Latest annual report
10-K · Mar 23, 2026

Companies similar to Cabaletta Bio

CABA peer companies
CompanyPrice% ChgMarket capCompare
LCTXLineage Cell Therapeutics Inc.0.7719-5.87%$195.26Mvs CABA
IPSCCentury Therapeutics Inc.1.17-11.74%$211.56Mvs CABA
ARTVArtiva Biotherapeutics Inc.3.78-1.31%$186.85Mvs CABA
ALLOAllogene Therapeutics Inc.0.6277-5.88%$217.48Mvs CABA
IKTInhibikase Therapeutics Inc.1.32+1.54%$185.16Mvs CABA
SCTXScribe Therapeutics Inc.12.07-8.70%$228.58Mvs CABA
CGENCompugen Ltd.1.84-2.13%$174.29Mvs CABA
AUTLAutolus Therapeutics plc ADR0.9073-7.38%$241.65Mvs CABA

Related